PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Established Benefits, Ongoing Research Drives Growth in the U.S. CoenzymeQ10 Markets - CoenzymeQ10 is a potent antioxidant well-recognized for its proven heart health benefits, including its ability to aid in the production of cellular energy, support healthy vision, alleviate migraines and reduce infertility
Established Benefits, Ongoing Research Drives Growth in the U.S. CoenzymeQ10 Markets

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2008/05/13 - CoenzymeQ10 is a potent antioxidant well-recognized for its proven heart health benefits, including its ability to aid in the production of cellular energy, support healthy vision, alleviate migraines and reduce infertility.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

These benefits, along with a rise in preventive healthcare, drive the U.S. supplements market for CoQ10.

New analysis from Frost & Sullivan (food.frost.com), U.S. CoenzymeQ10 Markets, finds the market earned revenues of over $80.6 million in 2007 and estimates to reach $199.8 million in 2014.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the U.S. CoQ10 markets, send an email to Johanna Haynes, Corporate Communications, at jhaynes_pr[.]frost.com with the following information: your full name, company name, title, company telephone number, company email address, city, state, and country. We will send you the information via email upon receipt of the above information.

The main tasks facing CoQ10 ingredient manufacturers are to establish scientific credibility and effectively communicate the product's benefits to consumers. By doing so, manufacturers will help drive the market in currently dominant applications such as supplements and help generate demand in the functional food and beverage category.

Manufacturers must continue research to reveal new benefits of the product if they are to maintain or grow market share, as scientific corroboration of the benefits of CoQ10 is essential to convince consumers to opt for this product.

Other ingredient markets in prebiotics and phytonutrients have seen leading manufacturers successfully leverage scientific credibility to develop a strong brand. New entrants must be prepared to invest substantially in scientific trials and clinical research to establish credibility, which will play an invaluable role in developing a distinct brand identity.

Meanwhile, as the population of the U.S. ages, consumer concern about mobility and quality of life will increase. The body's ability to synthesize CoQ10 in human tissues decreases with age, and this could have serious consequences. CoQ10 supplements, therefore, will find greater uptake among the elderly.

Burgeoning product development in the market also opens up newer venues of growth for CoQ10 manufacturers. For example, new product development activities reveal new application areas for CoQ10, which is likely to drive market growth. Potential application areas include the food and beverages market.

Since manufacturers of functional foods and beverages choose from a wide range of nutrients when deciding to add to their products, the taste and sensory acceptability of CoQ10 products is very important.

Research has shown that consumers are unwilling to compromise on taste, texture, and other organoleptic properties when it comes to functional food. Technical service and formulation assistance are increasingly necessary tools in developing markets.

U.S. CoenzymeQ10 Markets is part of the Food & Beverage Ingredients Growth Partnership Service program, which also includes research in the following markets: Europe CoenzymeQ10 market, U.S. prebiotics markets, global lutein market, and U.S. essential oils and oleoresins market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

U.S. CoenzymeQ10 Markets N106

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Established Benefits, Ongoing Research Drives Growth in the U.S. CoenzymeQ10 Markets

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Johanna Haynes 
210.247.3870 johanna.haynes[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)